Abstract
Legislation and prospective legislative proposals in for instance the USA, Europe, and Japan require, or may require that chemicals are tested for their ability to disrupt the hormonal systems of mammals. Chemicals found to test positive are considered to be endocrine active substances (EAS) and may be putative endocrine disruptors (EDs). To date, there is still little or no experience with incorporating metabolic and toxicokinetic aspects into in vitro tests for EAS. This is a situation in sharp contrast to genotoxicity testing, where in vitro tests are routinely conducted with and without metabolic capacity. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review paper reviews why in vitro assays for EAS should incorporate mammalian systems of metabolism and metabolic enzyme systems, and indicates how this could be done. The background to ED testing, the available test methods, and the role of mammalian metabolism in the activation and the inactivation of both endogenous and exogenous steroids are described. The available types of systems are compared, and the potential problems in incorporating systems in in vitro tests for EAS, and how these might be overcome, are discussed. Lastly, some recommendations for future activities are made.
Keywords: Endocrine disruption, endocrine active substances, metabolism, cytochrome P450, estrogenicity, androgenicity
Current Drug Metabolism
Title: The Use of Metabolising Systems for In Vitro Testing of Endocrine Disruptors
Volume: 9 Issue: 8
Author(s): M. N. Jacobs, W. Janssens, U. Bernauer, E. Brandon, S. Coecke, R. Combes, P. Edwards, A. Freidig, A. Freyberger, R. Kolanczyk, C. Mc Ardle, O. Mekenyan, P. Schmieder, T. Schrader, M. Takeyoshi and B. van der Burg
Affiliation:
Keywords: Endocrine disruption, endocrine active substances, metabolism, cytochrome P450, estrogenicity, androgenicity
Abstract: Legislation and prospective legislative proposals in for instance the USA, Europe, and Japan require, or may require that chemicals are tested for their ability to disrupt the hormonal systems of mammals. Chemicals found to test positive are considered to be endocrine active substances (EAS) and may be putative endocrine disruptors (EDs). To date, there is still little or no experience with incorporating metabolic and toxicokinetic aspects into in vitro tests for EAS. This is a situation in sharp contrast to genotoxicity testing, where in vitro tests are routinely conducted with and without metabolic capacity. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review paper reviews why in vitro assays for EAS should incorporate mammalian systems of metabolism and metabolic enzyme systems, and indicates how this could be done. The background to ED testing, the available test methods, and the role of mammalian metabolism in the activation and the inactivation of both endogenous and exogenous steroids are described. The available types of systems are compared, and the potential problems in incorporating systems in in vitro tests for EAS, and how these might be overcome, are discussed. Lastly, some recommendations for future activities are made.
Export Options
About this article
Cite this article as:
Jacobs N. M., Janssens W., Bernauer U., Brandon E., Coecke S., Combes R., Edwards P., Freidig A., Freyberger A., Kolanczyk R., Mc Ardle C., Mekenyan O., Schmieder P., Schrader T., Takeyoshi M. and Burg van der B., The Use of Metabolising Systems for In Vitro Testing of Endocrine Disruptors, Current Drug Metabolism 2008; 9 (8) . https://dx.doi.org/10.2174/138920008786049294
DOI https://dx.doi.org/10.2174/138920008786049294 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Discovery of New Aminosubstituted Pyrrolopyrimidines with Antiproliferative Activity Against Breast Cancer Cells and Investigation of their Effect Towards the PI3Kα Enzyme
Anti-Cancer Agents in Medicinal Chemistry Amyloid-β Peptides, Alzheimer's Disease and the Blood-brain Barrier
Current Alzheimer Research Anti-HER2 Treatment and Breast Cancer: State of the Art, Recent Patents, and New Strategies
Recent Patents on Anti-Cancer Drug Discovery Meet Our Editorial Board Member
Protein & Peptide Letters A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines
Current Drug Discovery Technologies Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism GPER and ER: Estrogen Receptors with Distinct Biological Roles in Breast Cancer
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Molecular Mechanisms, Proteinopathies and Therapeutic Strategies in Neurodegenerative Disorders
Current Genomics Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma
Current Drug Discovery Technologies Congenital Choledochal Malformation – Current Concepts and Classification
Current Pediatric Reviews Novel Drug Delivery Systems for Sustained and Targeted Delivery of Anti-Cancer Drugs: Current Status and Future Prospects
Current Drug Delivery Patent Selections
Recent Patents on Anti-Cancer Drug Discovery New Emerging Trends in Protein and Peptide Based Therapeutic Approaches – Part I
Current Protein & Peptide Science Impact of Computational Structure-Based Predictive Toxicology in Drug Discovery
Combinatorial Chemistry & High Throughput Screening The Role and Significance of Unconventional Hydrogen Bonds in Small Molecule Recognition by Biological Receptors of Pharmaceutical Relevance
Current Pharmaceutical Design Galvez-Markov Network Transferability Indices: Review of Classic Theory and New Model for Perturbations in Metabolic Reactions
Current Drug Metabolism Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry